ARTICLE | Clinical News
ALT-71: Began Phase IIb trial
October 29, 2001 8:00 AM UTC
Alteon Inc. (ALT), Ramsey, N.J. Product: ALT-711 Business: Metabolic Therapeutic category: Metabolism Target: A.G.E.s Description: Thiazolium compound, advanced glycosylation end-product (A.G.E.) cro...